DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wcdqdk/pharmapoint_type) has announced the addition of the "PharmaPoint: Type 2 Diabetes - Japan Drug Forecast and Market Analysis to 2022" report to their offering.
Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians.
Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.
A dip in sales caused by Actos patent expiry in 2012 and three insulin products' patent expiry by 2015 will be offset by 16 pipeline product launches over the forecast period. Byetta's patent expiration in 2016 will not have a major impact on the market as its sales have been constantly declining, with Victoza and Bydureon overtaking its shares. Since the Japanese regulatory system requires safety trials to be conducted in Japanese patients, pipeline products will launch later in this country than in the other six major markets.
Product Profiles - Major Brands
- Metformin
- Sulfonylureas (SUs) and Other Insulin Secretagogues
- a-glucosidase Inhibitors (AGIs)
- Thiazolidinediones (TZDs)
- GLP-1 Receptor Agonists
- DPP-4 Inhibitors
- SGLT-2 Inhibitors
- Insulin Formulations
Promising Drugs in Clinical Development
- Albiglutide
- Dulaglutide (LY2189265)
- Semaglutide
- Trelagliptin (SYR-472)
- MK-3102
- Empagliflozin
- Tofogliflozin
- Ipragliflozin
- Fasiglifam (TAK-875)
- LY2409021
- LY2605541 (insulin peglispro)
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Market Outlook
9 Appendix
For more information visit http://www.researchandmarkets.com/research/wcdqdk/pharmapoint_type
